News

GSK is to stop paying doctors to talk about its drugs and attend conferences

BMJ 2014; 347 doi: https://doi.org/10.1136/bmj.f7579 (Published 03 January 2014) Cite this as: BMJ 2014;347:f7579

This article has a correction. Please see:

  1. Zosia Kmietowicz
  1. 1BMJ

The UK based pharmaceutical giant GlaxoSmithKline has said that by the start of 2016 it will stop paying doctors to speak on its behalf or to attend conferences, to end undue influence on prescribers.

In an announcement on 17 December GSK also said that it planned to remove individual sales targets from its sales force, meaning that drug representatives would no longer be paid according to the number of prescriptions they solicited from the doctors they saw.

Instead GSK is introducing a new performance related scheme that will reward sales representatives for their technical knowledge, the quality of the service they deliver to support improved care of patients, …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe